Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Monopar Therapeutics Inc ( (MNPR) ) has shared an update.
On September 23, 2025, Monopar Therapeutics Inc. entered into an Underwriting Agreement to issue and sell shares of Common Stock and pre-funded warrants, expected to generate approximately $91.9 million in net proceeds. Additionally, the company announced a stock repurchase agreement with Tactic Pharma, conditioned on the closing of the offering. Furthermore, Monopar announced that the Journal of Hepatology published a letter demonstrating that their investigational therapy ALXN1840 significantly improved copper balance in Wilson disease patients, addressing previous methodological limitations.
The most recent analyst rating on (MNPR) stock is a Buy with a $106.00 price target. To see the full list of analyst forecasts on Monopar Therapeutics Inc stock, see the MNPR Stock Forecast page.
Spark’s Take on MNPR Stock
According to Spark, TipRanks’ AI Analyst, MNPR is a Neutral.
Monopar’s overall stock score is primarily affected by its financial performance challenges, such as negative cash flows and lack of revenue. However, the strong cash position and debt-free status provide some stability. The technical indicators show neutral market sentiment, while the new CFO appointment brings a positive strategic outlook. The valuation reflects typical biotech hurdles with a negative P/E ratio.
To see Spark’s full report on MNPR stock, click here.
More about Monopar Therapeutics Inc
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs. The company is involved in late-stage development of ALXN1840 for Wilson disease and has radiopharmaceutical programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, as well as Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers.
Average Trading Volume: 51,098
Technical Sentiment Signal: Buy
Current Market Cap: $450.7M
For a thorough assessment of MNPR stock, go to TipRanks’ Stock Analysis page.